TCM
CCCC icon

TCG Crossover Management’s C4 Therapeutics CCCC Stock Holding History

TCG Crossover Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,276,574
Closed -$5.9M – 37
2024
Q2 		$5.9M Hold
1,276,574
– – 0.61% 26
2024
Q1 		$10.4M Hold
1,276,574
– – 0.82% 27
2023
Q4 		$7.21M Hold
1,276,574
– – 0.8% 26
2023
Q3 		$2.37M Hold
1,276,574
– – 0.35% 26
2023
Q2 		$3.51M Buy
1,276,574
+26,574
+2% +$85.4K 0.58% 21
2023
Q1 		$3.92M Buy
+1,250,000
New +$7.36M 0.77% 21

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCG Crossover Management's CCCC Position: Q3 2024 in Review

TCG Crossover Management sold out of C4 Therapeutics (CCCC) in Q3 2024, closing a stake of 1,276,574 shares — an estimated $5.9M sold.

TCG Crossover Management first reported a position in CCCC in Q1 2023 and held it in 6 quarters. The position peaked at $10.4M in Q1 2024. 118 funds tracked by Wall St. Rank hold CCCC as of Q3 2024.

  • TCG Crossover Management reported no remaining C4 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • TCG Crossover Management sold 1,276,574 C4 Therapeutics shares in Q3 2024, an estimated $5.9M.
  • TCG Crossover Management first reported a position in C4 Therapeutics in Q1 2023 and held it in 6 quarters.
  • TCG Crossover Management's C4 Therapeutics position peaked at $10.4M in Q1 2024.
  • 118 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2024.

Based on TCG Crossover Management's 13F filing for Q3 2024, filed 14 Nov 2024.